{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/parkinsons-disease/diagnosis/differential-diagnosis/","result":{"pageContext":{"chapter":{"id":"435dc95c-73c1-5636-953b-feb3d7f82aaf","slug":"differential-diagnosis","fullItemName":"Differential diagnosis","depth":2,"htmlHeader":"<!-- begin field 22e06ed7-55c6-457f-85c2-c5f513d037c1 --><h2>What else might it be?</h2><!-- end field 22e06ed7-55c6-457f-85c2-c5f513d037c1 -->","summary":"","htmlStringContent":"<!-- begin item 5636c801-effc-4c12-9fe7-04333855ffcd --><!-- begin field 14b8941e-cc82-4d6e-b089-567bfb689c9f --><p><strong>Other causes of parkinsonism include: </strong></p><ul><li><strong>Drug-induced parkinsonism</strong> — note: it is often not possible to distinguish between Parkinson's disease and drug-induced parkinsonism on the basis of clinical symptoms and signs alone. It typically presents with motor symptoms that are rapid in onset and bilateral; there is often no rigidity or resting tremor, and there may be an action tremor. Possible causative drugs include:<ul><li>Antipsychotics (parkinsonism symptoms usually appear within 10 weeks of starting the drug): <ul><li>In general, second-generation antipsychotics (such as amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, sertindole, and zotepine) are less likely to cause parkinsonism than first-generation antipsychotics (such as fluphenazine, trifluorophenazine, haloperidol, chlorpromazine, flupentixol, and zuclopenthixol).</li></ul></li><li>Anti-emetics: <ul><li>Prochlorperazine.</li><li>Metoclopramide.</li></ul></li><li>Other drugs (more rarely):<ul><li>Antidepressants, such as selective serotonin reuptake inhibitors (SSRIs).</li><li>Calcium-channel blockers.</li><li>Cinnarizine.</li><li>Amiodarone.</li><li>Lithium.</li><li>Cholinesterase inhibitors, such as donepezil or memantine.</li><li>Sodium valproate.</li><li>Methyldopa.</li><li>Pethidine.</li></ul></li></ul></li><li><strong>Medical conditions</strong><ul><li>Cerebrovascular disease — such as repeated strokes with stepwise progression. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/stroke-tia/\">Stroke and TIA</a> for more information.</li><li>Non-Parkinson's dementia (including dementia with Lewy bodies and Alzheimer's disease). See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/dementia/\">Dementia</a> for more information.</li><li>Other neurodegenerative parkinsonian syndromes, which involve a wider area of the nervous system than idiopathic Parkinson's disease, such as:<ul><li>Progressive supranuclear palsy (suggested by early dysphagia, gaze palsy, or recurrent falls). </li><li>Multiple system atrophy (suggested by severe early autonomic involvement such as postural hypotension, or cerebellar ataxia). </li><li>Corticobasal degeneration (suggested by asymmetric rigidity and dystonia, with apraxia and cognitive impairment). </li></ul></li><li>Wilson's disease (suggested by Kayser-Fleischer rings caused by deposition of copper in the membrane of the cornea; variable neurological signs including tremor, ataxia, and dystonia; and non-specific liver disease).</li><li>Repeated head injury. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/head-injury/\">Head injury</a> for more information.</li></ul></li></ul><p><strong>Other causes of tremor include:</strong></p><ul><li><strong>Postural and action tremor</strong><ul><li>Essential tremor<ul><li>Note: essential tremor and Parkinson's disease may co-exist, and differentiating between the two conditions can be difficult clinically.</li><li>Essential tremor is common; onset is at any age, and often there is a family history.</li><li>Typically tremor is bilateral and symmetrical; may worsen with stress, caffeine, sleep deprivation; typically involves the head, neck, or voice as well as the limbs; and often improves with alcohol and beta-blockers. </li></ul></li><li>Exaggerated physiological tremor.</li><li>Dystonic tremor<ul><li>May affect the head and usually presents in young adults.</li></ul></li><li>Hyperthyroidism. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hyperthyroidism/\">Hyperthyroidism</a> for more information.</li><li>Drugs, such as beta-<sub>2 </sub>agonists.</li></ul></li><li><strong>Intention tremor</strong><ul><li>Cerebellar disorders.</li></ul></li></ul><!-- end field 14b8941e-cc82-4d6e-b089-567bfb689c9f --><!-- end item 5636c801-effc-4c12-9fe7-04333855ffcd -->","topic":{"id":"6cfe5031-c78a-5fcf-8597-8688ef0d3a41","topicId":"ac61656d-8e8b-48b8-bf1d-49f506afadb6","topicName":"Parkinson's disease","slug":"parkinsons-disease","lastRevised":"Last revised in February 2018","chapters":[{"id":"8bebf6b8-3a72-530a-ac48-52a8618f2267","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"044ab1d2-584c-5ed9-ab24-f7c8d64ef959","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"51b4e173-4f8a-5f7a-9e4a-fff68f32b031","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"29a7b8ce-d32b-5e9d-a682-56084e34b727","slug":"changes","fullItemName":"Changes"},{"id":"e1bb005f-8b49-5ae3-9670-a888d5def19a","slug":"update","fullItemName":"Update"}]},{"id":"fbbb2e6c-5309-5aa6-a27f-d6f508b6f994","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"40c62f24-40c5-5619-88aa-963a7de0d17d","slug":"goals","fullItemName":"Goals"},{"id":"2b0ddbc1-3535-545a-8be3-996ce778ee4d","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"a8f322a5-4ac1-50c9-8391-83584bd86b30","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"d2a1f92e-43cd-575e-bcbd-7bd0e6792634","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"e860c3e6-3288-5ee1-bd77-a6d4aa0c3006","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"d3463e24-bbaa-5d3a-aca9-0d6da87a47f3","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"644e166b-8434-55a7-859c-6479b609051a","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"935e4ed2-12f3-5857-9a26-8a3beaed429c","slug":"definition","fullItemName":"Definition"},{"id":"58a49a4b-fb27-55f3-9afb-3c816842a76a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"ce592a68-6b1f-5015-8125-2facfdcc4afe","slug":"prognosis","fullItemName":"Prognosis"},{"id":"8a05334f-9e7a-5662-b166-d86bd3c7546e","slug":"complications","fullItemName":"Complications"}]},{"id":"3951c9c0-49fe-5d17-8d1d-4c42b0b95c3f","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"e7662ffa-e42d-5bb5-9025-2ba5f6587a6f","slug":"when-to-suspect","fullItemName":"When to suspect"},{"id":"435dc95c-73c1-5636-953b-feb3d7f82aaf","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"196d12bb-51bd-5a0b-872d-c7b60bde431b","fullItemName":"Management","slug":"management","subChapters":[{"id":"38b7e750-e77e-5791-a127-6e5192b69597","slug":"suspected-parkinsons-disease","fullItemName":"Scenario: Suspected Parkinson's disease"},{"id":"fae10e1b-26bc-523c-bc3b-ec45e56860ca","slug":"confirmed-parkinsons-disease","fullItemName":"Scenario: Confirmed Parkinson's disease"},{"id":"c0adefb6-a71d-5b3c-bc2d-b86a13219e16","slug":"end-stage-parkinsons-disease","fullItemName":"Scenario: End-stage Parkinson's disease"}]},{"id":"d811822d-b022-5b69-8514-00e15d349643","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"83038956-9818-52c8-9415-85ab073e43aa","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"757d939c-8a84-5a32-847b-38d850b38230","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"17a6cb12-1c93-5aff-bc74-2c2cee2f97ee","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"bd851d10-0cce-5204-8b2e-54ae60c5767f","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"9d232b23-7764-59d5-8026-50fff91a905b","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"7deed303-b70d-5459-8ca1-d40e9dbf3c88","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"1a717fd3-80b2-587f-8d46-3f904380d76a","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"3951c9c0-49fe-5d17-8d1d-4c42b0b95c3f","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"36a09eb0-1bd7-5a24-b382-97cdc23257ab","slug":"basis-for-recommendation-c2b","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field e64e76f0-ac9b-42ee-998e-008555d42124 --><h3>Basis for recommendation</h3><!-- end field e64e76f0-ac9b-42ee-998e-008555d42124 -->","summary":null,"htmlStringContent":"<!-- begin item c2ba0c42-aa83-41d3-88aa-8bcb5ae6ff65 --><!-- begin field 92b412d1-0fff-48ee-b372-5f10c28a9e04 --><p>The information on other causes of parkinsonism and tremor is based on the clinical guideline produced by the National Institute for Health and Care Excellence (NICE) <em>Parkinson's disease in adults: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/parkinsons-disease/references/\">NICE, 2017</a>], the Scottish Intercollegiate Guidelines Network (SIGN) clinical guideline <em>Diagnosis and pharmacological management of Parkinson's disease</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/parkinsons-disease/references/\">SIGN, 2010</a>], expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/parkinsons-disease/references/\">Clarke, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/parkinsons-disease/references/\">Grosset, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/parkinsons-disease/references/\">Breen, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/parkinsons-disease/references/\">Kalia, 2015</a>], and expert opinion in the British National Formulary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/parkinsons-disease/references/\">BNF 74, 2017</a>].</p><h4>Differentiating Parkinson's disease from drug-induced parkinsonism</h4><ul><li>The information on the typical presenting features of drug-induced parkinsonism is based on expert opinion in a review article <em>Drug-induced parkinsonism</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/parkinsons-disease/references/\">Hirose, 2006</a>].</li><li>The information on cholinesterase inhibitors is based on a Cochrane systematic review <em>Cholinesterase inhibitors for Parkinson's disease dementia (Cochrane Review)</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/parkinsons-disease/references/\">Maidment et al, 2006</a>].</li></ul><h4>Differentiating Parkinson's disease from Wilson's disease</h4><ul><li>The information on possible clinical features of Wilson's disease is based on expert opinion in the European Association for the Study of the Liver <em>EASL Clinical practice guidelines: Wilson's disease</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/parkinsons-disease/references/\">European Association for the Study of the Liver, 2012</a>].</li></ul><h4>Differentiating Parkinson's disease from essential tremor</h4><ul><li>The information on the distinguishing features of essential tremor is based on expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/parkinsons-disease/references/\">Ng, 1996</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/parkinsons-disease/references/\">Rao et al, 2003</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/parkinsons-disease/references/\">Rao et al, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/parkinsons-disease/references/\">Jankovic, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/parkinsons-disease/references/\">Weintraub et al, 2008</a>].</li></ul><!-- end field 92b412d1-0fff-48ee-b372-5f10c28a9e04 --><!-- end item c2ba0c42-aa83-41d3-88aa-8bcb5ae6ff65 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}